UBS Group AG Sells 9,460 Shares of The Cooper Companies, Inc. (NYSE:COO)

UBS Group AG lowered its position in The Cooper Companies, Inc. (NYSE:COO – Get Rating) by 23.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 31,692 shares of the medical device company’s stock after selling 9,460 shares during the quarter. UBS Group AG owned about 0.06% of Cooper Companies worth $10,480,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. ProShare Advisors LLC lifted its position in Cooper Companies by 0.4% during the fourth quarter. ProShare Advisors LLC now owns 6,700 shares of the medical device company’s stock valued at $2,215,000 after purchasing an additional 28 shares during the last quarter. Citadel Advisors LLC lifted its position in Cooper Companies by 122.7% during the third quarter. Citadel Advisors LLC now owns 56,089 shares of the medical device company’s stock valued at $14,802,000 after purchasing an additional 30,899 shares during the last quarter. Eaton Vance Management lifted its position in Cooper Companies by 17.0% during the third quarter. Eaton Vance Management now owns 86,091 shares of the medical device company’s stock valued at $22,720,000 after purchasing an additional 12,525 shares during the last quarter. Securian Asset Management Inc. lifted its position in Cooper Companies by 2.5% during the fourth quarter. Securian Asset Management Inc. now owns 4,054 shares of the medical device company’s stock valued at $1,341,000 after purchasing an additional 100 shares during the last quarter. Finally, Xponance Inc. increased its position in shares of Cooper Companies by 17.4% during the 4th quarter. Xponance Inc. now owns 6,580 shares of the medical device company’s stock valued at $2,176,000 after purchasing an additional 974 shares during the last quarter. Institutional investors own 96.78% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on COO. Stifel Nicolaus increased their price objective on Cooper Companies from $380.00 to $420.00 in a research report on Tuesday, May 16th. Mizuho boosted their price target on shares of Cooper Companies from $390.00 to $400.00 in a research note on Tuesday, April 18th. Wells Fargo & Company boosted their price target on shares of Cooper Companies from $355.00 to $430.00 in a research note on Monday, May 15th. Robert W. Baird boosted their price target on shares of Cooper Companies from $371.00 to $385.00 in a research note on Friday, March 3rd. Finally, TheStreet raised shares of Cooper Companies from a “c+” rating to a “b-” rating in a research note on Friday, April 14th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $393.30.

Cooper Companies Trading Up 1.0 %

COO opened at $390.14 on Tuesday. The business has a 50 day simple moving average of $372.61 and a two-hundred day simple moving average of $344.62. The firm has a market capitalization of $19.30 billion, a price-to-earnings ratio of 51.67, a PEG ratio of 2.76 and a beta of 0.91. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.72 and a quick ratio of 1.00. The Cooper Companies, Inc. has a one year low of $244.21 and a one year high of $395.20.

Cooper Companies (NYSE:COO – Get Rating) last released its quarterly earnings results on Thursday, March 2nd. The medical device company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.66 by $0.24. The business had revenue of $858.50 million during the quarter, compared to analyst estimates of $834.90 million. Cooper Companies had a return on equity of 8.39% and a net margin of 11.10%. Cooper Companies’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.24 EPS. Analysts predict that The Cooper Companies, Inc. will post 12.73 EPS for the current year.

Insider Activity

In other news, Director Robert S. Weiss sold 37,510 shares of Cooper Companies stock in a transaction dated Tuesday, March 7th. The shares were sold at an average price of $337.72, for a total transaction of $12,667,877.20. Following the sale, the director now owns 70,000 shares of the company’s stock, valued at approximately $23,640,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Cooper Companies news, Director Robert S. Weiss sold 37,510 shares of the stock in a transaction on Tuesday, March 7th. The stock was sold at an average price of $337.72, for a total value of $12,667,877.20. Following the completion of the transaction, the director now owns 70,000 shares in the company, valued at $23,640,400. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Gerard H. Warner III sold 1,216 shares of the business’s stock in a transaction that occurred on Thursday, March 9th. The stock was sold at an average price of $340.53, for a total value of $414,084.48. Following the completion of the sale, the chief operating officer now directly owns 1,290 shares in the company, valued at $439,283.70. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 39,726 shares of company stock valued at $13,451,962. Corporate insiders own 2.00% of the company’s stock.

About Cooper Companies

(Get Rating)

The Cooper Cos, Inc operates as a medical device company. It operates through the Cooper Vision and Cooper Surgical segments. The Cooper Vision segment develops, manufactures, and markets products for contact lens wearers, which solves vision challenges such as astigmatism, presbyopia, myopia, ocular dryness, and eye fatigues.